EUVIMEDEUVIMED entdecken
Crossref

Functional Proteomics of Quinazolin‐4‐One Derivatives Targeting the Proteasome

Elva Morretta iD, Claudia Finamore, Rosa Barbato, Simona De Marino, Ivana Bello, Elisabetta Panza, Matteo Mozzicafreddo iD, Angela Zampella, Carmen Festa iD, Maria Chiara Monti iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.202500728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Elva Morretta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Naples "Federico II", Via D. Montesano, 49, I-80131, Naples, Italy. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Quinazolinones, Proteomics, Proteasome Inhibitors. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quinazolinones have been recently recognized as valuable scaffolds for developing novel therapeutic opportunities. They indeed exhibit structural versatility and a wide range of biological activities, including antifungal, antitubercular, antihypertensive, anticancer, and antiviral ones. In this work, a focused library of new bioactive 4‐(3‐H)‐quinazolinones has been synthesized, their cytotoxic action against DU‐145 prostate cancer cells has been detailed, and compound 4k has been revealed as the most active one. Consequently, its interactome has been characterized by a label‐free functional proteomics‐based platform coupling drug affinity responsive target stability (DARTS) and targeted limited proteolysis‐multiple reaction monitoring‐mass spectrometry (t‐LiP‐MRM‐MS). This multifaced strategy has been employed to reveal few subunits of the 26S proteasome machinery as the most reliable compound 4k biological targets. This paved the way for the deepening of the protein–ligand interaction using in vitro and in silico bio‐orthogonal techniques. Finally, the analysis of its function in living DU‐145 cells prompted compound 4k as a novel quinazolinone‐bearing inhibitor of the chymotrypsin‐like activity of the proteasomal β −5 subunit, stirring this framework for the development of new anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome Endopeptidase ComplexQuinazolinonesProteomicsProteasome InhibitorsAntineoplastic AgentsHumansStructure-Activity RelationshipCell Line, TumorMolecular StructureDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

anticancerproteasome inhibitorproteomicsquinazolin‐4‐onestarget identification

Substanzen

Proteasome Endopeptidase ComplexQuinazolinonesProteasome InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, University of Naples "Federico II", Via D. Montesano, 49, I-80131, Naples, Italy.
  • Department of Clinical and Molecular Sciences, Marche Polytechnic University, Via Tronto, 10, 60126, Ancona, Italy.

ORCID-Profile: Elva Morretta, Matteo Mozzicafreddo, Carmen Festa, Maria Chiara Monti

Zitieren

APA

Morretta, E., Finamore, C., Barbato, R., De Marino, S., Bello, I., Panza, E., Mozzicafreddo, M., Zampella, A., Festa, C., & Monti, M. C. (2026). Functional Proteomics of Quinazolin‐4‐One Derivatives Targeting the Proteasome. ChemMedChem. https://doi.org/10.1002/cmdc.202500728

Vancouver

Morretta E, Finamore C, Barbato R, De Marino S, Bello I, Panza E, et al. Functional Proteomics of Quinazolin‐4‐One Derivatives Targeting the Proteasome. ChemMedChem. 2026. doi:10.1002/cmdc.202500728

BibTeX
@article{Morretta2026,
  author = {Morretta, Elva and Finamore, Claudia and Barbato, Rosa and De Marino, Simona and Bello, Ivana and Panza, Elisabetta and Mozzicafreddo, Matteo and Zampella, Angela and Festa, Carmen and Monti, Maria Chiara},
  title = {Functional Proteomics of Quinazolin‐4‐One Derivatives Targeting the Proteasome},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202500728}
}
Kostenlos starten →